期刊
CLINICAL INFECTIOUS DISEASES
卷 50, 期 11, 页码 1487-1492出版社
OXFORD UNIV PRESS INC
DOI: 10.1086/652441
关键词
-
资金
- National Institute of Allergy and Infectious Diseases [N01-AI-70005-CEIRS H1N1 P8]
- ALSAC
Background. The world is facing a novel H1N1 influenza pandemic. A pandemic scare with a similar influenza virus in 1976 resulted in the vaccination of nearly 45 million persons. We hypothesized that prior receipt of the 1976 swine flu vaccine would enhance immune responses to the 2009 novel H1N1 influenza strain. Methods. A prospective, volunteer sample of employees aged >= 55 years at a children's cancer hospital in August 2009 was assessed for antibody responses to the 2009 pandemic H1N1 influenza virus and the 2008-2009 seasonal H1N1 influenza virus. Results. Antibody responses by hemagglutination-inhibition assay were high against both the seasonal influenza virus (89.7% had a titer considered seroprotective) and pandemic H1N1 influenza virus (88.8% had a seroprotective titer). These antibodies were effective at neutralizing the seasonal H1N1 influenza virus in 68.1% of participants (titer >= 40), but only 18.1% had detectable neutralizing titers against the pandemic H1N1 influenza virus. Of 116 participants, 46 (39.7%) received the 1976 swine flu vaccine. Receipt of this vaccine significantly enhanced neutralization responses; 8 (17.4%) of 46 vaccine recipients had titers >= 160, compared with only 3 (4.3%) of 70 who did not receive the vaccine (Pp. 018 by x 2 test). Conclusions. In this cohort, persons aged >= 55 years had evidence of robust immunity to the 2008-2009 seasonal H1N1 influenza virus. These antibodies were cross-reactive but nonneutralizing against the 2009 pandemic H1N1 influenza strain. Receipt of a vaccine to a related virus significantly enhanced the neutralization capacity of these responses, suggesting homologous vaccination against the 2009 pandemic H1N1 influenza virus would have a similar effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据